Stock Price & Analysis

Buy BBIO stock as analysts maintain a Strong Buy consensus with a significant upside potential of 72.8%. The stock is undervalued with positive momentum driven by strong commercial performance and pipeline progress.

BBIO stock is predicted to reach $46-$60 in 2025, driven by strong analyst sentiment and FDA approvals. Current price is $31.88, with a 72.8% upside potential. Analysts maintain a Strong Buy consensus, citing transformative therapies and commercial momentum.

The S1 support level for BBIO Stock is $31.1 ,The R1 resistant level for BBIO Stock is $34.66.

As of the end of day on 2025-03-14, the price of BBIO Stock was $31.71.

The target price for BBIO Stock according to analyst rating is 53.90, with the highest price target at 95.00 and the lowest at 37.00. Analysts have a Strong Buy rating on BBIO Stock overall.

The market cap of BBIO is $6.1B.

Analysis and Insights

Valuation Metrics

BridgeBio Pharma (BBIO) currently exhibits several concerning valuation metrics. The stock has a negative P/E ratio of -11.09, indicating significant losses. Additionally, the EV/EBITDA ratio is not available due to negative earnings, further highlighting profitability challenges. The price-to-sales (P/S) ratio is elevated, suggesting the stock may be overpriced relative to its revenue.

Financial Performance

The company has reported consistent net losses across all four quarters of 2024, with net income ranging from -$35.216 million to -$267.389 million. While revenue has grown, the inability to achieve profitability raises concerns about its valuation.

Technical Analysis

The stock's technical indicators suggest bearish momentum. The RSI (14) is at 42.21, indicating oversold conditions but not yet reaching extreme levels. The MACD is negative (-0.19), and the stock is trading near the lower end of its Bollinger Bands, signaling continued selling pressure.

Analyst Sentiment

Analysts are divided on BBIO. While some maintain a Strong Buy rating with a consensus price target of $54.00, others have raised concerns about profitability and insider selling. The stock has a negative insider sentiment score, with 33 insiders selling shares recently.

Conclusion

Based on the negative earnings, high valuation ratios, bearish technical indicators, and mixed analyst sentiment, BBIO appears overvalued. Investors should exercise caution and consider the significant risks before making any investment decisions.

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering, creating, testing and delivering transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. The Company's pipeline of development programs ranges from early science to advanced clinical trials that include Acoramidis (AG10), a next-generation small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of amyloidosis TTR (ATTR); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI), as a treatment option for children with achondroplasia; Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR) for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, an investigational, orally administered, small molecule substrate supplementation therapy that the Company is developing for the treatment of LGMD2I, also known as LGMDR9.

BBIO stock is predicted to reach $60 by 2030, driven by its strong pipeline of transformative medicines and recent FDA approvals. The company's focus on genetic diseases and cancers positions it for sustained growth. Analysts are optimistic about its commercial momentum and competitive market dynamics.

BBIO has a total of 550 employees.